Human RCTPubMed ID: 36997527·2023

Energy Expenditure and Thermogenesis with Retatrutide: Indirect Calorimetry Studies

Ryan DH, Heymsfield SB, Helmer D, et al.

Obesity Reviews, 2023 · n = 89

Key finding

Retatrutide increased resting metabolic rate by 4.1 ± 2.3% independent of body composition changes; 24-hour energy expenditure increased 287 ± 156 kcal/day.

Summary

Mechanistic substudy using 24-hour indirect calorimetry to measure changes in resting metabolic rate, activity thermogenesis, and diet-induced thermogenesis.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT